newsfilter
← Latest News
GlobeNewswire·

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

AURA
  • Aura Biosciences reports Q4 & full-year 2025 financial results with cash, cash equivalents & marketable securities totaling $144.2 million as of Dec 31, 2025.
  • The company expects to complete enrollment in the Phase 3 CoMpass trial for early choroidal melanoma by mid-2026, with topline data anticipated in H2 2027.
  • Initial 3-month clinical data from the Phase 1b/2 NMIBC trial is expected in mid-2026.
  • A new formulation of bel-sar has achieved 12-month stability, supporting potential use in non-ocular solid tumors starting with urologic oncology.
  • Research & development expenses were $90.3 million for the full year 2025, while general & administrative expenses decreased to $22.5 million.
  • Net loss for the full year 2025 was $106.2 million, compared to $86.9 million in 2024.
  • The Phase 2 trial for metastases to the choroid continues enrollment with early data expected in 2026.
  • A Phase 1 proof-of-concept trial for cancers of the ocular surface is initiating in Australia with data expected in 2026.
  • Cash reserves are sufficient to fund operations into Q1 2027.
  • The new formulation patent application, if issued, would provide coverage into 2046.